- Report
- April 2022
- 71 Pages
Global
From €3313EUR$3,495USD£2,767GBP
- Report
- February 2024
- 180 Pages
Global
From €4710EUR$4,969USD£3,935GBP
- Report
- August 2022
United States
From €1839EUR$1,940USD£1,536GBP
- Report
- August 2022
United States
From €1839EUR$1,940USD£1,536GBP
- Report
- August 2022
United States
From €1839EUR$1,940USD£1,536GBP
- Report
- August 2022
Global
From €1033EUR$1,090USD£863GBP
- Report
- August 2022
Global
From €1128EUR$1,190USD£942GBP
- Report
- August 2022
Global
From €1033EUR$1,090USD£863GBP
- Report
- February 2021
Global
From €2806EUR$2,960USD£2,344GBP
- Report
- July 2023
- 223 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- April 2021
- 191 Pages
Global
€20852EUR$22,000USD£17,420GBP
- Report
- November 2020
- 49 Pages
Global
€1249EUR$1,318USD£1,044GBP
- Drug Pipelines
- September 2019
- 118 Pages
Global
€9478EUR$10,000USD£7,918GBP
- Report
- April 2019
- 93 Pages
Global
From €3080EUR$3,250USD£2,573GBP
- Report
- August 2018
- 16 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Report
- August 2018
- 25 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Report
- August 2018
- 48 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Report
- August 2018
- 21 Pages
Global
From €9478EUR$10,000USD£7,918GBP
- Report
- August 2018
- 10 Pages
United States
From €1042EUR$1,099USD£870GBP
- Report
- August 2018
- 10 Pages
United States
From €1042EUR$1,099USD£870GBP

The Lung Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat lung cancer. These drugs are used to treat both non-small cell and small cell lung cancer, the two most common types of lung cancer. The drugs are designed to target the cancer cells and stop them from growing and spreading. Common treatments include chemotherapy, targeted therapy, immunotherapy, and radiation therapy.
The Lung Cancer Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies such as Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Roche are all major players in the market. These companies are constantly researching and developing new drugs to treat lung cancer, as well as improving existing treatments.
In addition, there are many smaller companies that specialize in the development of new drugs for the treatment of lung cancer. These companies often collaborate with larger pharmaceutical companies to bring their drugs to market. Examples of these companies include ImmunoGen, Inc., Oncolytics Biotech, and ImmunoCellular Therapeutics. Show Less Read more